目的 探討芪藶強(qiáng)心膠囊聯(lián)合吲達(dá)帕胺治療高血壓心力衰竭的臨床療效。方法 選取2016年1月—2017年1月在桐柏縣中醫(yī)院進(jìn)行治療的88例高血壓心力衰竭患者，隨機(jī)分為對(duì)照組（44例）和治療組（44例）；對(duì)照組口服吲達(dá)帕胺片，2.5 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療8周。治療后，觀察兩組患者臨床療效，同時(shí)比較治療前后兩組心功能和6 min步行試驗(yàn)（6WMT）、血清學(xué)指標(biāo)及不良反應(yīng)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為79.55%、95.45%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組左心室收縮末期內(nèi)徑（LVDS）、左心室舒張末期內(nèi)徑（LVEDD）均顯著降低，左室射血分?jǐn)?shù)（LVEF）、6WMT均明顯增加，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述觀察指標(biāo)顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者血清hs-CRP、β-EP、NT-proBNP和CT-1水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述指標(biāo)顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。兩組均無明顯不良反應(yīng)發(fā)生。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合吲達(dá)帕胺治療高血壓心力衰竭療效顯著，有利于患者心功能及機(jī)體細(xì)胞因子的改善，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the therapeutic effect of Qili Qiangxin Capsules combined with indapamide in treatment of hypertensive heart failure. Methods Patients (88 cases) with hypertensive heart failure in Tongbai Hospital of TCM from January 2016 to January 2017 were randomly divided into control (44 cases) and treatment groups (44 cases). Patients in the control group were po administered with Indapamide Tablets, 2.5 mg/time, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules, four grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and cardiac function, 6WMT, serum indexes, and adverse reactions in two groups before and after treatment were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 79.55% and 95.45%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVDS and LVEDD in two groups significantly decreased, but LVEF and 6WMT significantly increased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of hs-CRP, β-EP, NT-proBNP, and CT-1 in serum in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). There were no adverse reactions in two groups. Conclusion Qili Qiangxin Capsules combined with indapamide has a significant curative effect in treatment of hypertensive heart failure, can significantly improve the cardiac function and cytokines levels, which has a certain clinical application value.